肺癌治疗：全球市场

全球肺癌治疗市场规模预计将从 2025 年的 325 亿美元成长到 2030 年底的 495 亿美元，在 2025 年至 2030 年的预测期内，复合年增长率将达到 8.8%。

预计北美肺癌药物市场将从 2025 年的 174 亿美元成长到 2030 年底的 267 亿美元，在 2025 年至 2030 年的预测期内，复合年增长率将达到 8.9%。

欧洲肺癌治疗市场预计将从 2025 年的 79 亿美元成长到 2030 年底的 119 亿美元，在 2025 年至 2030 年的预测期内，复合年增长率将达到 8.3%。

本报告考察了全球肺癌治疗市场，提供了概述、市场影响因素和机会分析、技术和专利趋势、法律制度、市场规模趋势和预测、按各个细分市场和地区进行的详细分析以及主要企业的概况。

目录

第一章：执行摘要

• 市场展望
• 调查范围
• 市场概况
• 市场动态与成长要素
• 新兴技术
• 细分市场分析
• 区域分析
• 结论

第二章 市场概览

• 概述
• 宏观经济因素分析
• 美国关税对製药业的影响
• 医疗费用支出
• 地缘政治风险、贸易战、供应链中断
• GDP对製药业的影响
• 波特五力分析

第三章 市场动态

• 市场动态
• 市场驱动因素
• 肺癌病例增加
• 促进肺癌治疗领域的创新
• 参与企业增加研发支出
• 政府经费和医药品研究开发费用增加
• 市场限制因素
• 学名药竞争加剧和专利到期
• 肿瘤科医师短缺
• 低成本化疗药物的普及限制了先进治疗方法的发展。
• 市场机会
• 新治疗方法的需求日益增长
• 新兴市场
• 非吸烟者肺癌发生率增加

第四章 监管情势

• 概述
• 我们
• 欧洲
• 亚太地区

第五章：新兴技术与管道分析

• 概述
• AI
• 免疫疗法和细胞疗法
• 新型生物标记
• 临床试验分析
• 临床试验分析：按试验类型
• 临床试验分析：依实施情形
• 临床试验分析：按阶段
• 重点
• 专利分析
• 重点

第六章 市场区隔分析

• 细分市场
• 全球肺癌治疗市场：依癌症类型划分
• 重点
• 非小细胞肺癌
• 小细胞肺癌
• 全球肺癌治疗市场：依治疗领域划分
• 重点
• 标靶治疗
• 化疗
• 免疫疗法
• 按地区划分
• 全球肺癌治疗市场：按地区划分
• 重点
• 北美洲
• 欧洲
• 亚太地区
• 中东和非洲
• 南美洲

第七章 竞争讯息

• 重点
• 竞争格局
• 企业市场占有率分析
• 战略分析

第八章 全球肺癌治疗市场的永续性：ESG观点

• ESG简介
• 肺癌药物市场的永续性
• ESG观点
• 环境影响
• 社会影响
• 对管治的影响
• ESG风险评估
• 结论

第九章附录

• 调查方法
• 简称
• 资讯来源
• 公司简介
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• 新兴企业/市场颠覆者

The global market for lung cancer therapeutics is expected to grow from $32.5 billion in 2025 and is projected to reach $49.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 8.8% during the forecast period of 2025 to 2030.

The North American market for lung cancer therapeutics is expected to grow from $17.4 billion in 2025 and is projected to reach $26.7 billion by the end of 2030, at a CAGR of 8.9% during the forecast period of 2025 to 2030.

The European market for lung cancer therapeutics is expected to grow from $7.9 billion in 2025 and is projected to reach $11.9 billion by the end of 2030, at a CAGR of 8.3% during the forecast period of 2025 to 2030.

Report Scope

This report will provide detailed information on lung cancer therapeutics. This report analyzes the market trends for lung cancer therapeutics, providing data for 2024, estimates for 2025, projections of compound annual growth rates (CAGRs) through 2030 (forecast period: 2025-2030) and regional markets for lung cancer therapeutics. This report will highlight the current and future market potential of lung cancer therapeutics, providing a detailed analysis of the competitive environment. The report will cover regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key market players.

In this report, the market is segmented by cancer type into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). By therapeutic type, the market is segmented into targeted therapy, chemotherapy and immunotherapy.

The market has been segmented into five regions: North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. This report will also provide detailed analyses of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India. For market estimates, data will be provided for 2024, given the base year, along with data for 2025 and a forecast value for 2030.

The report aims to:

• Analyze types of lung cancer therapeutics.
• Analyze global market size and segments.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness and industry structure.
• Identify potential long-term impacts on the lung cancer therapeutics market.

Report Includes

• 86 data tables and 55 additional tables
• An overview of the global market for lung cancer therapeutics
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2025, as well as forecasts for 2030. This analysis includes projections of compound annual growth rates (CAGRs) through 2030
• Evaluation of the current market size and revenue growth prospects specific to the lung cancer therapeutics, accompanied by a market share analysis by type, therapeutics, and region
• Analysis of current and future demand in the lung cancer therapeutics market, along with a detailed analysis of the competitive environment, market regulations and reimbursement practices
• Analysis of drivers, challenges, and opportunities affecting market growth
• Coverage of evolving technologies, the current and future market potential, R&D activities, clinical trials, growth strategies, new product pipeline, regulatory framework and reimbursement scenarios, and ESG trends of the market
• Market share analysis of the key market participants in the industry, along with their research priorities, product portfolios, global rankings and company competitive landscape
• Profiles of major companies within the industry, including AstraZeneca, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Co., and Pfizer Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditure
• Geopolitical Risks, Trade Wars and Supply Chain Disruptions
• Impact of Global Economic Growth (GDP) on the Pharma Sector
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Lung Cancer Cases
• Increasing Innovation in Lung Cancer Therapeutics
• Increasing R&D Spending by Market Players
• Rise in Government Funding and Pharmaceutical R&D Spending
• Market Restraints
• Rising Generic Competition and Patent Expiration
• Shortage of Oncology Professionals
• Available Low-Priced Chemotherapeutics Limiting Growth of Advanced Therapies
• Market Opportunities
• Increasing Demand for Novel Therapies
• Emerging Markets
• Increasing Lung Cancer Incidence Among Non-Smokers

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence
• Immunotherapies and Cell Therapy
• Emergent Biomarkers
• Clinical Trial Analysis
• Clinical Trials Analysis by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Global Market for Lung Cancer Therapeutics, by Cancer Type
• Key Takeaways
• Non-Small Cell Lung Cancer
• Small Cell Lung Cancer
• Global Market for Lung Cancer Therapeutics, by Therapeutic
• Key Takeaways
• Targeted Therapy
• Chemotherapy
• Immunotherapy
• Geographic Breakdown
• Global Market for Lung Cancer Therapeutics, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Company Share Analysis
• Strategic Analysis

Chapter 8 Sustainability in the Global Market for Lung Cancer Therapeutics: An ESG Perspective

• Introduction to ESG
• Sustainability in the Lung Cancer Therapeutics Market
• ESG Perspective
• Environmental Impact
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• ASTRAZENECA
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC.
• MERCK & CO. INC.
• NOVARTIS AG
• PFIZER INC.
• REGENERON PHARMACEUTICALS INC.
• TAKEDA PHARMACEUTICAL CO. LTD.
• TEVA PHARMACEUTICAL INDUSTRIES LTD.
• Emerging Players/Market Disruptors

List of Tables

• Summary Table : Global Market for Lung Cancer Therapeutics, by Region, Through 2030
• Table 1 : Health Expenditure, by Country, 2021-2023
• Table 2 : Lung Cancer Statistics, by Region 2022 and 2023
• Table 3 : NCI Funding, by Mechanism, 2020-2024
• Table 4 : Selected Approved Biosimilars in the Market
• Table 5 : Clinical Trials in Lung Cancer Therapeutics, by Type of Study, as of November 2025
• Table 6 : Clinical Trials in Lung Cancer Therapeutics, by Status, as of November 2025
• Table 7 : Clinical Trials in Lung Cancer Therapeutics, by Phase, as of November 2025
• Table 8 : List of Selected Lung Cancer Therapeutics Clinical Trial Studies, 2025
• Table 9 : List of Selected Recently Granted Patents Related to Lung Cancer Therapeutics, 2024-2025
• Table 10 : Global Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 11 : Global Market for NSCLC in Lung Cancer Therapeutics, by Region, Through 2030
• Table 12 : Global Market for SCLC in Lung Cancer Therapeutics, by Region, Through 2030
• Table 13 : Global Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 14 : Selected Approved Targeted Therapies in the Lung Cancer Therapeutics Market
• Table 15 : Global Market for Targeted Therapy in Lung Cancer Therapeutics, by Region, Through 2030
• Table 16 : Selected Approved Chemotherapies in the Lung Cancer Therapeutics Market
• Table 17 : Global Market for Chemotherapy in Lung Cancer Therapeutics, by Region, Through 2030
• Table 18 : Selected Approved Immunotherapies in the Lung Cancer Therapeutics Market
• Table 19 : Global Market for Immunotherapy in Lung Cancer Therapeutics, by Region, Through 2030
• Table 20 : Global Market for Lung Cancer Therapeutics, by Region, Through 2030
• Table 21 : North American Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 22 : North American Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 23 : North American Market for Lung Cancer Therapeutics, by Country, Through 2030
• Table 24 : U.S. Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 25 : U.S. Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 26 : Canadian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 27 : Canadian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 28 : Mexican Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 29 : Mexican Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 30 : European Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 31 : European Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 32 : European Market for Lung Cancer Therapeutics, by Country, Through 2030
• Table 33 : German Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 34 : German Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 35 : U.K. Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 36 : U.K. Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 37 : French Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 38 : French Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 39 : Italian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 40 : Italian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 41 : Spanish Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 42 : Spanish Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 43 : Rest of Europe Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 44 : Rest of Europe Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 45 : Lung Cancer Cases in Asia-Pacific, by Region, 2022
• Table 46 : Asia-Pacific Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 47 : Asia-Pacific Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 48 : Asia-Pacific Market for Lung Cancer Therapeutics, by Country, Through 2030
• Table 49 : Chinese Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 50 : Chinese Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 51 : Japanese Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 52 : Japanese Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 53 : Indian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 54 : Indian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 55 : South Korean Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 56 : South Korean Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 57 : Australian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 58 : Australian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 59 : Rest of Asia-Pacific Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 60 : Rest of Asia-Pacific Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 61 : MEA Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 62 : MEA Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 63 : MEA Market for Lung Cancer Therapeutics, by Sub-Region, Through 2030
• Table 64 : Middle Eastern Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 65 : Middle Eastern Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 66 : African Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 67 : African Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 68 : South American Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 69 : South American Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 70 : South American Market for Lung Cancer Therapeutics, by Country, Through 2030
• Table 71 : Brazilian Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 72 : Brazilian Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 73 : Argentine Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 74 : Argentine Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 75 : Rest of South America Market for Lung Cancer Therapeutics, by Cancer Type, Through 2030
• Table 76 : Rest of South America Market for Lung Cancer Therapeutics, by Therapeutic, Through 2030
• Table 77 : Key Strategic Initiatives in Lung Cancer Therapeutics Market, 2024-2025
• Table 78 : Key Focus Areas in ESG Metrics
• Table 79 : ESG Rankings for Leading Companies in Lung Cancer Therapeutics, 2025*
• Table 80 : Abbreviations Used in this Report
• Table 81 : Report Sources
• Table 82 : AbbVie Inc.: Company Snapshot
• Table 83 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 84 : AbbVie Inc.: Product Portfolio
• Table 85 : AbbVie Inc.: News/Key Developments, 2025
• Table 86 : Amgen Inc.: Company Snapshot
• Table 87 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 88 : Amgen Inc.: Product Portfolio
• Table 89 : Amgen Inc.: News/Key Developments, 2023-2025
• Table 90 : AstraZeneca: Company Snapshot
• Table 91 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 92 : AstraZeneca: Product Portfolio
• Table 93 : AstraZeneca: News/Recent Developments, 2022-2025
• Table 94 : Boehringer Ingelheim International GmbH: Company Snapshot
• Table 95 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2023 and 2024
• Table 96 : Boehringer Ingelheim International GmbH: Product Portfolio
• Table 97 : Boehringer Ingelheim International GmbH: News/Key Developments, 2025
• Table 98 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 99 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 100 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 101 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
• Table 102 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 103 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 104 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 105 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
• Table 106 : Jazz Pharmaceuticals Inc.: Company Snapshot
• Table 107 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 108 : Jazz Pharmaceuticals Inc.: Product Portfolio
• Table 109 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2025
• Table 110 : Johnson & Johnson: Company Snapshot
• Table 111 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 112 : Johnson & Johnson Services Inc.: Product Portfolio
• Table 113 : Johnson & Johnson Services Inc.: News/Key Developments, 2022-2025
• Table 114 : Lilly USA LLC.: Company Snapshot
• Table 115 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
• Table 116 : Lilly USA LLC.: Product Portfolio
• Table 117 : Lilly USA LLC.: News/Key Development, 2022-2025
• Table 118 : Merck & Co. Inc.: Company Snapshot
• Table 119 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 120 : Merck & Co. Inc.: Product Portfolio
• Table 121 : Merck & Co. Inc.: News/Key Developments, 2022-2025
• Table 122 : Novartis AG: Company Snapshot
• Table 123 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 124 : Novartis AG: Product Portfolio
• Table 125 : Novartis AG: News/Key Developments, 2022
• Table 126 : Pfizer Inc.: Company Snapshot
• Table 127 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
• Table 128 : Pfizer Inc.: Product Portfolio
• Table 129 : Pfizer Inc.: News/Key Developments, 2023-2025
• Table 130 : Regeneron Pharmaceuticals Inc.: Company Snapshot
• Table 131 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 132 : Regeneron Pharmaceuticals Inc.: Product Portfolio
• Table 133 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
• Table 134 : Takeda Pharmaceutical Co. Ltd.: Company Snapshot
• Table 135 : Takeda Pharmaceutical Co. Ltd.: Financial Performance, FY 2023 and 2024
• Table 136 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
• Table 137 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
• Table 138 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
• Table 139 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
• Table 140 : A Few Emerging Players in the Lung Cancer Therapeutics Market

List of Figures

• Summary Figure : Global Market Shares of Lung Cancer Therapeutics, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Lung Cancer Therapeutics Market
• Figure 2 : Market Dynamics of Lung Cancer Therapeutics
• Figure 3 : Global Shares of Five-Year Prevalence Cases of Lung Cancer, by Region, 2022
• Figure 4 : Global Market Shares of Companies' R&D Expenditure, by Function, 2022
• Figure 5 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
• Figure 6 : Global Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 7 : Global Market Shares of NSCLC in Lung Cancer Therapeutics, by Region, 2024
• Figure 8 : Global Market Shares of SCLC in Lung Cancer Therapeutics, by Region, 2024
• Figure 9 : Global Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 10 : Global Market Shares of Targeted Therapy in Lung Cancer Therapeutics, by Region, 2024
• Figure 11 : Global Market Shares of Chemotherapy in Lung Cancer Therapeutics, by Region, 2024
• Figure 12 : Global Market Shares of Immunotherapy in Lung Cancer Therapeutics, by Region, 2024
• Figure 13 : Global Market Shares of Lung Cancer Therapeutics, by Region, 2024
• Figure 14 : North American Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 15 : North American Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 16 : North American Market Shares of Lung Cancer Therapeutics, by Country, 2024
• Figure 17 : U.S. Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 18 : U.S. Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 19 : Canadian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 20 : Canadian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 21 : Mexican Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 22 : Mexican Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 23 : European Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 24 : European Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 25 : European Market Shares of Lung Cancer Therapeutics, by Country, 2024
• Figure 26 : German Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 27 : German Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 28 : U.K. Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 29 : U.K. Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 30 : French Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 31 : French Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 32 : Italian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 33 : Italian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 34 : Spanish Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 35 : Spanish Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 36 : Rest of Europe Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 37 : Rest of Europe Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
• Figure 38 : Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 39 : Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
• Figure 40 : Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Country, 2024
• Figure 41 : Chinese Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 42 : Chinese Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 43 : Japanese Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 44 : Japanese Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 45 : Indian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 46 : Indian Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
• Figure 47 : South Korean Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 48 : South Korean Market Shares of Lung Cancer Therapeutics, by Therapeutics, 2024
• Figure 49 : Australian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 50 : Australian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 51 : Rest of Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 52 : Rest of Asia-Pacific Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 53 : MEA Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 54 : MEA Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 55 : MEA Market Shares of Lung Cancer Therapeutics, by Sub-Region, 2024
• Figure 56 : Middle Eastern Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 57 : Middle Eastern Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 58 : African Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 59 : African Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 60 : South American Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 61 : South American Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 62 : South American Market Shares of Lung Cancer Therapeutics, by Country, 2024
• Figure 63 : Brazilian Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 64 : Brazilian Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 65 : Argentine Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 66 : Argentine Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 67 : Rest of South America Market Shares of Lung Cancer Therapeutics, by Cancer Type, 2024
• Figure 68 : Rest of South America Market Shares of Lung Cancer Therapeutics, by Therapeutic, 2024
• Figure 69 : Top 10 Blockbuster Lung Cancer Therapeutics, by Sales Revenue, 2023-2024
• Figure 70 : Global Market Shares of Lung Cancer Therapeutics, by Company, 2024
• Figure 71 : Pillars of ESG
• Figure 72 : Advantages of ESG for Companies
• Figure 73 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 74 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 75 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 76 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 77 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
• Figure 78 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
• Figure 79 : Boehringer Ingelheim International GmbH: Revenue Shares, by Business Unit, FY 2024
• Figure 80 : Boehringer Ingelheim International GmbH: Revenue Shares, by Region, FY 2024
• Figure 81 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
• Figure 82 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
• Figure 83 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 84 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 85 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 86 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 87 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
• Figure 88 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
• Figure 89 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
• Figure 90 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
• Figure 91 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 92 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 93 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 94 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 95 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 96 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 97 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 98 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 99 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, FY 2024
• Figure 100 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Country/Region, FY 2024
• Figure 101 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2024